RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
This bill revises Rhode Island’s Uniform Controlled Substances Act, primarily by updating statutory definitions and opioid-prescribing rules. It adds and revises terms such as acute pain, chronic pain, chronic intractable pain, opioid therapy, therapeutic purpose, and other controlled-substance definitions, while also modernizing language throughout the chapter. The bill specifically changes the framework for prescribing opioids by removing fixed dosage and supply limits tied to certain provisions and replacing them with a more practice-based standard that emphasizes professional judgment, documentation, review of the prescription drug monitoring program, and compliance with Department of Health regulations.
The bill also restructures the rules governing opioid prescribing for acute pain, minors, cancer pain, palliative care, sickle cell pain, and chronic intractable pain. It requires practitioners to use the lowest effective dose, review the prescription drug monitoring program before starting or refilling opioid therapy, document treatment decisions, and offer naloxone in certain circumstances. At the same time, it preserves exceptions for substance use disorder treatment medications and allows the Department of Health to issue regulations and best-practice guidance. In addition, the bill repeals the separate chapter on intractable pain treatment and folds related concepts into the controlled substances chapter.
The bill would amend multiple sections of chapter 21-28 of the General Laws, changing how controlled substances—especially opioids—are defined, prescribed, and regulated in Rhode Island. It would eliminate the standalone Intractable Pain Treatment Act in chapter 5-37.4 and replace it with updated provisions inside the Uniform Controlled Substances Act, thereby consolidating pain-treatment rules under the Department of Health’s controlled-substances authority. The measure would affect practitioners, pharmacists, patients receiving opioid therapy, minors, and patients with chronic intractable pain, cancer-related pain, palliative care needs, or sickle cell-related pain.
Based on the bill text and the absence of recorded committee testimony or votes, the overall tone appears policy-driven and technical rather than overtly partisan. The bill’s stated purpose is to align the law with current standards of professional practice while preserving safeguards such as monitoring-program review, documentation, and naloxone access. Its structure suggests support for both opioid stewardship and continued access to pain treatment, indicating an attempt to balance public health concerns with clinical flexibility.
The main point of contention is likely the shift away from rigid statutory opioid dosage limits toward broader practitioner discretion. Supporters may view this as necessary to reflect modern medical practice and to avoid one-size-fits-all restrictions for acute, cancer, palliative, and chronic intractable pain patients. Critics may worry that removing specific limits could weaken guardrails against overprescribing or diversion, even though the bill retains monitoring, documentation, and regulatory oversight requirements. Another likely area of debate is the repeal of the separate intractable pain statute and whether consolidating these rules could improve clarity or instead reduce protections for pain patients.